PharmaLedger – First Report on Dissemination and Exploitation Activities

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives
support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Copyright © PharmaLedger Consortium 2020 – 2023 PharmaLedger: www.pharmaledger.eu IMI: www.imi.europa.eu
D6.12 First Report on Dissemination
and Exploitation Activities
Deliverable No D6.12
Work package No. and Title WP6 Culture and Adoption
Version - Status V1.0 (final)
Date of Issue 07/10/2021
Dissemination Level PUBLIC
Filename D6.12 First Report on Dissemination and Exploitation Activities v1.0
Ref. Ares(2021)6181417 - 11/10/2021

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives
support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Copyright © PharmaLedger Consortium 2020 – 2023 PharmaLedger: www.pharmaledger.eu IMI: www.imi.europa.eu
Copyright © 2020-2022, PharmaLedger Consortium
Disclaimer: Any information on this deliverable solely reflects the author’s view and neither IMI nor the European Union or EFPIA
are responsible for any use that may be made of the information contained herein.
This document and its contents remain the property of the beneficiaries of the PharmaLedger Consortium and may not be re-
used, distributed or reproduced without the expressed written approval of the PharmaLedger Coordinators, Maria Eugenia Beltran
and Daniel Fritz (Universidad Politécnica de Madrid and Novartis respectively; contact@pharmaledger.eu)
THIS DOCUMENT AND INFORMATION IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND ANY EXPRESS
OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE COPYRIGHT OWNER OR CONTRIBUTORS BE LIABLE FOR ANY
DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO,
PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR
OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS DOCUMENT, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE

PharmaLedger – 853992 | Deliverable D6.12 v1.0 | PUBLIC 3/42
DOCUMENT INFO
Authors
Author Organization e-mail
Tamanna KHAN TVS Tamanna@technovativesolutions.co.uk
Document History
Date Version Editor Change Status
11/03/2021 0.1 Tamanna Khan Initial Draft Version with TOC draft
30/04/2021 0.2 Tamanna Khan
Draft with Introduction and
high level of Dissemination
activities
draft
18/07/2021 0.3 Tamanna Khan Draft with Exploitation Section draft
13/09/2021 0.4 Dan Fritz Feedback on the draft draft
04/10/2021 0.5 Hirkirit Virdee Updated draft draft
05/10/2021 0.6 Maria Eugenia BELTRAN
Feedback on the draft and
comments
draft
07/10/2021 0.7 Tamanna Khan Final Draft
Final
draft
08/10/2021 1.0
Cecilia Vera/Maria Eugenia
Beltran
Final review and formatting Final
Disclaimer: Any information on this deliverable solely reflects the author’s view and neither IMI nor the European
Union or EFPIA are responsible for any use that may be made of the information contained herein.

PharmaLedger – 853992 | Deliverable D6.12 v1.0| PUBLIC 4/42
TABLE OF CONTENT
EXECUTIVE SUMMARY........................................................................................................................... 6
1. INTRODUCTION ............................................................................................................................. 7
2. DISSEMINATION ACTIVITIES .......................................................................................................... 7
2.1 Project Website ..................................................................................................................... 8
2.2 Social Media........................................................................................................................... 9
2.3 PharmaLedger Newsletters ................................................................................................... 9
2.4 Blogs, Featured Articles & News Mentions ......................................................................... 10
2.5 Press Releases...................................................................................................................... 11
2.6 Webinars and Videos........................................................................................................... 11
2.7 External Events .................................................................................................................... 12
2.8 Liaison with other projects .................................................................................................. 16
2.9 Scientific Publication............................................................................................................ 16
2.10 Demonstrations ................................................................................................................... 16
2.11 Coordination with other European Projects and Regulatory and Standardisation Bodies.. 17
3. NEXT PLANNED DISSEMINATION ACTIONS.................................................................................. 17
3.1 Dissemination through external events............................................................................... 17
3.2 Open Access Scientific Publication ...................................................................................... 21
4. EXPLOITATION ACTIVITIES ........................................................................................................... 23
4.1 Identification of the Exploitation Results and Stakeholders................................................ 24
4.2 Governance Options for the Exploitation Routes................................................................ 25
4.3 Individual Exploitation Plan ................................................................................................. 26
4.3.1 Pharma Stakeholders:.................................................................................................. 26
4.3.2 Technical Stakeholders: ............................................................................................... 26
4.3.3 Hospitals: ..................................................................................................................... 26
4.3.4 Patient Organisations: ................................................................................................. 26
4.3.5 Universities and Research Organisations:.................................................................... 26
4.4 Business Plan ....................................................................................................................... 26
4.4.1 Phase 1 Market Analysis:............................................................................................. 27
4.4.2 Phase 2 Competitor’s Analysis:.................................................................................... 28
4.4.3 Phase 3 SWOT.............................................................................................................. 29
4.4.4 Phase 4 Stakeholder Analysis....................................................................................... 29
4.4.5 Phase 5 Business Model Value Proposition................................................................. 32
4.4.6 Phase 6 IPR and Licenses ............................................................................................. 32
4.4.7 Phase 7 Financial Planning & Revenue Models ........................................................... 32
4.4.8 Phase 8 Marketing Plan ............................................................................................... 32
5. CONCLUSION ............................................................................................................................... 35
APPENDIX ............................................................................................................................................ 36
Annex 1: News Mentions and Featured Articles ............................................................................. 36
Annex 2: Blog Posts ......................................................................................................................... 39
Annex 3: PharmaLedger Videos....................................................................................................... 42

LIST OF FIGURES
Figure 1: PharmaLedger Website .......................................................................................................... 8
Figure 2: PharmaLedger Internal and External Newsletters................................................................ 10
Figure 3: Pharmaledger Featured Article............................................................................................. 10
Figure 4: PharmaLedger December 2020 Press Release ..................................................................... 11
Figure 5: PharmaLedger ePi Brochure................................................................................................. 16
Figure 6: Roadmap for the Future Conferences .................................................................................. 21
Figure 7: PharmaLedger use cases....................................................................................................... 23
Figure 8: Exploitation Planning, Activities and Timeline...................................................................... 24
Figure 9: Recommended Post-PharmaLedger Operating Model......................................................... 25
Figure 10: Different Phases of the Business Plan ................................................................................ 28
Figure 11: Stakeholder Engagement process ...................................................................................... 30
Figure 12: Sample Stakeholder mapping............................................................................................. 31
Figure 13: Content Marketing Funnel.................................................................................................. 32
LIST OF TABLES
Table 1: PharmaLedger Website in numbers ........................................................................................ 8
Table 2: Social Media in numbers.......................................................................................................... 9
Table 3: Newsletters in numbers (as of 30 June 2021)........................................................................ 10
Table 4: No of blogs, articles and mentions (as of 30 June 2021) ....................................................... 10
Table 5: External Event in 2020 ........................................................................................................... 13
Table 6: External Event in 2021 ........................................................................................................... 15
Table 7: Journal Publication................................................................................................................. 16
Table 8: Examples of Potential Scientific Journals.............................................................................. 22
ACRONYMS
DRA Domain Reference Application
DSU Data Sharing Units
D&C Dissemination & Communication
EC European Commission
WP Work Package
IMI Innovative Medicine Initiative
H2020 Horizon 2020 EU Research and Innovation Program
SCP Social Collaboration Platform
ICT Information, Communication and Technology
SME Small and Medium-Sized Enterprises
ePi Electronic Product Information
MVP Minimum Valuable Product
PMB Project Management Board

EXECUTIVE SUMMARY
This deliverable describes all dissemination and exploitation activities we (PharmaLedger Consortium)
conducted from Month 1 to Month 18 (January 2020 – June 2021). D6.12 complements the deliverable
D6.11 Dissemination and in-project exploitation plan (M6), which describes PharmaLedger’s
Dissemination, communication, and exploitation strategy to maximise the project impacts.
We have divided this document into three main sections; the first two provides a detailed description
of the dissemination activities and next planned dissemination, and the third presents the updated
exploitation plan and activities.
Due to the Covid-19, we have mostly relied on the virtual dissemination activities. This increased
PharmaLedger’s opportunity to present in the international and multidisciplinary events.
PharmaLedger project has achieved, during the last 18 months, a relevant acknowledgement and a
relevant position in the healthcare ecosystem and blockchain / digital technologies due to the
awareness events, the use case definitions, and research carried out during the project. Furthermore,
the project's impact has been raised due to the development of the blockchain-based platform,
focused on the use cases in three Domain Reference Applications (DRAs): Supply Chain, Clinical Trials
and Health Data, which is in the process of implementation. Keeping in mind the achievements
developed by the project, the PharmaLedger consortium has executed the dissemination and
exploitation activities to maximise impact and expose the project results.
During the first half of the project, the dissemination and communication activities have focused on
presenting and demonstrating the use cases developed in the three DRAs at different events and
conferences (such as DIA Europe, European Blockchain Congress, LogiPharma, Scope, etc.).
Furthermore, regarding the exploitation activities during the first 18 months, the partners are
coordinating with other European projects and regulatory and standardisation bodies and continuing
the groundwork on the post-project governance and operating model (WP4).
The key Dissemination and Exploitation activities carried out by the project during the first half (18 M)
can be summed up as in the following:
• PharmaLedger was present through different discussions, keynotes, speeches, lectures, and
panels in 41 important and reputed international conferences and events. However, due to
the COVID-19 outbreak, most of the events were held virtually.
• A PharmaLedger member published 1 journal article which covers blockchain innovations
through supply chain use cases.
• The ePi use case leaders have disseminated the use case demo (ePi) has in various events
(such as DIA Europe 2021, PHARMAP 2021 etc.).
• PharmaLedger Website is launched at M3 and continuously updated with new contents
achieved incredible numbers in terms of visitors (9800) and the average time spent on the
website (1 min 29 sec).
• 20 Newsletters, 3 Press releases, 38 Blog posts, and 18 Featured articles were produced and
circulated through the website, PharmaLedger community and PharmaLedger’s extensive
network of contacts.
• PharmaLedger received 20 News mentions from different articles, blog posts and published
reports including a prominent mention of Novartis and Merck by Forbes article as the
‘Blockchain Top Global 50 of 2021’.
• The very bold and active presence of PharmaLedger on social channels: In total, the project
reached 2484 followers through different social media such as Linkedin, Twitter, Facebook,
YouTube etc.
• 3 Webinars (one internal and two open) arranged by PharmaLedger with 836 registrations.

1. INTRODUCTION
In PharmaLedger, WP6: Culture and Adoption is responsible for promoting and disseminating
PharmaLedger concepts and outcomes. With such purpose, this document reports the achievements
and activities related to the dissemination and exploitation of the PharmaLedger project from M1 to
M18 (January 2020- June 2021).
The document is organised in three sections corresponding to different types of activities as follows:
• Section 2 reports on dissemination and public activities are undertaken jointly by the
consortium and individually by the partners in the first half of the project lifetime.
• Section 3 summarises the next planned dissemination activities that will be carried out during
the second half of the PharmaLedger project.
• Finally, section 4 details the exploitation activities executed by the partners, along with
updated plans for the rest of the project, concerning the knowledge and results generated
within PharmaLedger during the first half of the project.
This report also summarises the key relevant aspects and strategic achievements in this area.
2. DISSEMINATION ACTIVITIES
As described in PharmaLedger's dissemination, exploitation and communication strategy (D6.1 and
D6.11), the PharmaLedger consortium has used a combination of physical and digital channels to
promote project activities and results to increase stakeholder awareness. Activities carried out by
consortium partners have continued to consolidate bold project visibility within the healthcare
ecosystem, blockchain and other digital technologies.
The entire consortium and partners individually have been involved in many activities, ranging from
event and standards participations to keynote presentable and panels and prepared material for
booths and presentations. The project communication has focused on raising awareness of the project
across various channels (website, social media, patients’ forums and communities, large worldwide
conferences and exhibitions). The goal is to reach the target stakeholders in the healthcare ecosystem
and blockchain technologies with highlights and public presentations of the project use cases and the
initial technical results for the PharmaLedger blockchain architecture and governance design. In
addition, the active involvement with the different regulatory and its various Working Groups (WGs)
in the health care at large has granted further opportunities for the project team to discuss approaches
and directions, together with presentations of plans and results.
From day one, the activities in dissemination and communication have been given top priority in the
project, allowing to properly propagating the inner value behind all the efforts and research carried
out in PharmaLedger.
The summary of top remarkable results achieved is presented below, reporting on project activities in
different dissemination areas:
• Project website

• Social Media
• Newsletter, press release, blogs, featured articles, news mentions
• Project webinars and videos
• Participations in events
• Demonstrations
• Liaison with other projects
• Scientific publications
• Demonstrations
2.1 Project Website
The project website1
(Figure 1) was launched in March 2020 (see D6.1 PharmaLedger website and
communication tool) and has since been used to disseminate project activities. The website traffic is
monitored using google analytics. The project website also hosts a repository that enables project-
related publications and other dissemination materials such as articles, blog posts, explainer videos,
interviews, newsletters etc.
Figure 1: PharmaLedger Website
PharmaLedger Website Analytics
Total Visitors (till M18) 9800
Average Engagement Time 1 min 29 sec
Table 1: PharmaLedger Website in numbers
1
www.pharmaledger.eu

2.2 Social Media
The consortium has used LinkedIn2
, Twitter3
, Youtube4
and Facebook5
as its social media platforms for
sharing project related information and achievements. In addition, the project has posted over 25 blog
posts with an impressive number of subscribers (>3000 subscribers).
LinkedIn
LinkedIn
Engagement
Group Twitter YouTube FaceBook
Total Followers/subscribers 1142 143 397 116 686
Total Visits 4356 N/A 13674 3886 N/A
Table 2: Social Media in numbers
2.3 PharmaLedger Newsletters
PharmaLedger has been publishing monthly internal and external newsletters since September 2020
to disseminate the consortium activities, especially events attendance, featured articles and news
mentions. The project has published 10 internal and 10 external newsletters. Both newsletters are
circulated to the subscribers via mailchimp. The subscription for the internal newsletters is only
limited to the participants of the consortium member organisations. The subscriptions for the external
newsletters are open to the public and collected via the project website.
2
www.linkedin.com/company/pharmaledger
3
https://twitter.com/pharmaledger
4
PharmaLedger Blockchain Enabled Healthcare - YouTube
5
https://www.facebook.com/pharmaledger.eu

Figure 2: PharmaLedger Internal and External Newsletters
Newsletters
Internal
Newsletter
External
Newsletters
Number of Newsletters published (June 2021) 10 10
Number of Subscribers 58 932
Table 3: Newsletters in numbers (as of 30 June 2021)
2.4 Blogs, Featured Articles & News Mentions
PharmaLedger captures any news mentions about the project and reshares them in social media and
the newsletters. PharmaLedger has also regularly written blog posts on some key news mentions and
the key events, webinars etc. Further, we have written featured articles on blockchain technology, use
cases etc6
.
Figure 3: Pharmaledger Featured Article
The following table gives an overview of the number of blogs, articles and mentions:
Number of Blog posts 38
Number of Featured Articles 18
Number of News Mentions 20
Table 4: No of blogs, articles and mentions (as of 30 June 2021)
6
https://pharmaledger.eu/news/

A complete list of the blog posts, featured articles and news mentions are given in Annex 1
2.5 Press Releases
The PharmaLedger consortium has released three official press releases. The press releases were
circulated in January 2020, in June 2020 and in December 2020, respectively. The press releases are
circulated to the Pharmaledger consortium via email; further, they can be viewed and downloaded
from the website. An example of the PharmaLedger press release can be seen below:
Figure 4: PharmaLedger December 2020 Press Release
2.6 Webinars and Videos
The consortium has hosted three webinars (one internal-only accessible for the consortium members
and two public) in the first half of the project. The first internal PharmaLedger Webinar took place in
July 2020, where consortium members were invited to participate and listen in on an introduction of
WP2 and WP3. The first open webinar, "A Trust-Centric Healthcare Journey", to the public presented
the latest progress on the PharmaLedger's Supply Chain use cases in November-December 2020. The
second open webinar, "A Trust-Centric Healthcare Journey 2", to the public presented the latest
progress on the PharmaLedger's Clinical Trail and Health Data use cases in March 2021. More
information on these webinars is documented in D6.15: First Report on PharmaLedger workshops and
events.

PharmaLedger also created and shared two explainer videos (Blockchain explained and Electronic
Product Information (ePi) use case). The third explainer video is already in the pipeline for production
(Anti-counterfeiting use case). In addition, the PharmaLedger open webinars and some of the event
presentations are also available in video format on the PharmaLedger website and YouTube channel.
A list of PharmaLedger videos are mentioned in Annex 3.
2.7 External Events
The consortium members have actively participated in 41 important and well-known events during
the first 18 months, giving presentations, keynotes, panel discussions and demonstrations related to
PharmaLedger. In addition, for each event, PharmaLedger updated and produced dissemination
materials such as social posts, banners etc.
The complete list of events with PharmaLedger participation are reported in the following table:
Event Date Venue Description PharmaLedger
Presence
Participant
EyeforPharma 31 March
- 3 April
2020
Virtual Eyeforpharma Barcelona is an event that unites
market access executives, key market access
authorities and pharma Ieadership from across the
commercial and clinical spectrum.
PharmaLedger
presentation
NVS
EL.E.F.I 16-17
June
2020
Virtual The Hellenic Society of Pharmaceutical Medicine
(EL.E.F.I.) is a nonprofit scientific society,
established in 1991 in Athens. EL.E.F.I.’s main
objective is to advance the general scientific activity
within the pharmaceutical industry landscape,
primarily focusing on clinical research,
pharmacovigilance and regulatory issues related to
medicines development and approval.
PharmaLedger
presentation
DUT
DIA Europe 2020 29 June -
03 July
2020
Virtual
Meeting –
Brussels,
Belgium
DIA Europe 2020 is Europe’s largest neutral
healthcare conference, which is attended by life
science professionals working in drug development,
from discovery to marketed use.
PharmaLedger
Virtual Booth
VNVS, TVS,
UPM, ABV
Blockchain for
Healthcare Event
16
Septemb
er 2020
Virtual -
Basel,
Switzerlan
d
#BC4HC addresses the technological and
regulatory trends in blockchain technology and how
this affects its application in healthcare.
Presentation on
PharmaLedger,
Supply Chain
use cases and
Identity &
Privacy
NVS
(Regulatory Intelligence
Discussion Group)
Meeting Q3 2020
17
Septemb
er 2020
Virtual (Regulatory Intelligence Discussion Group) Meeting
Q3 2020
Presented in the
"Regulatory
Intelligence
Discussion
Group.
NVS
European Blockchain
Convention Virtual
Edition 2020
21-22
Septemb
er 2020
Virtual
Edition –
Barcelona,
Spain
The European Blockchain Convention (EBC) brings
together more than 1.500 attendees from all over
Europe and includes panel discussions and
presentations from over 100 industry experts.
Virtual Booth,
PharmaLedger
introduction,
Supply chain
and Clinical Trial
use case
UPM, NVS,
UCB, MSD,
TVS
EU Blockchain
Observatory & Forum
24
Septemb
er 2020
Virtual This workshop organised by the Observatory and
Forum focused on Blockchain applications in
Healthcare.
PharmaLedger
architecture
NVS, ROM
DIA Future of Evidence
Workshop
7-9
October
2020
Virtual Premier event for regulatory bodies PharmaLedger
presentation
NVS
Internet Festival 2020 -
Forms of Future
8-11
October
2020
Live and
Virtual -
Pisa, Italy
This four day festival in Italy covered various topics
revolving around the latest Internet technology. This
year’s theme was titled #Reset, as digitisation is
rapidly transforming how we live and work.
PharmaLedger
governance
presentation
UPM
Digital Transformation
Forum
14
October
2020
Virtual This inaugural Digital Transformation Forum virtual
conference focused on the future of enterprise
technology and the current state of Blockchain
adoption.
PharmaLedger
Clinical Supply
use case
NVS, PFE

Pharma Supply Chain,
Serialization, and Anti-
Counterfeiting
21 Oct
2020
Virtual This virtual event focused on the latest
developments and innovations in Pharma
Serialization and Anti-Counterfeiting, including
industry trends such as air cargo, best practices of
aggregation, analytics of serialization data, and an
end-to-end supply chain visibility.
PharmaLedger
Supply chain
use case
NVS
2020 Global Blockchain
Week
26-28
October
2020
Virtual -
Toronto,
Ontario
The second edition of the Blockchain Revolution
Global (BRG) 2020 event brought together
executives from the world’s leading enterprises
alongside foremost leaders, thinkers, and
practitioners in blockchain. Co-hosted by the
Blockchain Research Institute and MCI Group, BRG
aims to educate, inspire, and prepare leaders to
participate in the revolutionary transformation that
blockchain technology is bringing to business,
government and society.
Panel
discussion,
“Integrated
Supply Chains
Ecosystems.”
NVS
Digital Days Basel 1-3
Novemb
er 2020
Virtual and
Live –
Switzerlan
d
The Digital Days Basel event focused on nine topics:
Work 4.0, education, e-democracy, health, lifestyle,
media & news, my data, mobility and smart city.
Under the direction of digitalswitzerland, this free
event covers digitisation a tangible experience to
promote dialogue on the subject with over 300
events and 90 speakers across the country.
Blockchain
ecosystems
regarding the
healthcare
industry
NVS
ISPE Annual Meeting 2-6
Novemb
er 2020
Virtual The 2020 ISPE Annual Meeting & Expo focused on
steering the future of pharmaceutical science and
manufacturing toward a more global, synchronised
and quality-driven industry.
Participated in
the panel
discussion,
“Integrated
Supply Chains
Ecosystems.”
NVS
DECHEMA e.V. 4
Novemb
er 2020
Virtual The DECHEMA e.V. Autumn Special – The
Blockchain Forge event covered how blockchain
technology is relevant to the process industry, how
it can be applied and the “pros” and “cons” of this
technology.
”Blockchain-
anchored
Identities and
credentials
enabling digital
transformation in
Pharma.”
NVS
LogiPharma Europe 9-12
Novemb
er 2020
Virtual The LogiPharma Europe event focuses on the
healthcare supply chain. This event focused on how
Covid-19 brought many changes in the global supply
chain. Topics included: delivering patient-centric
solutions, preparing global supply chains for Covid-
19 vaccines and treatments, and using digital
innovation to drive end-to-end stakeholder
collaboration.
Supply chain &
Block chain
NVS, J&J,
MSD,
BAYER
Bio Supply Management
Alliance (BSMA)
Conference
12
Novemb
er 2020
Virtual This BSMA Conference connects and supports
collaboration among the worldwide community of
operations, supply chain management leaders and
professionals in the biotech, biopharma, and
biomedical device industries
“Tracking of
pharma products
using blockchain
and IoT.”
BAYER
Global Blockchain
Creative
16 & 23
Novemb
er 2020
Virtual The Global Blockchain Creative helps organizations
to apply blockchain for improved efficiency, security,
and transparency within their business, and their
ecosystem
PharmaLedger
presentation
NVS
Himss Blockchain
Taskforce
18 Nov
2020
Virtual Himss Blockchain Taskforce PharmaLedger
presentation
NVS
Pharma Middle East
Virtual Congress
7-8
Decemb
er 2020
Virtual Pharma Middle East Virtual Congress (PMC2020)
layout many new ideas to resolve the most important
problems related to the health and wellbeing of
humanity
PharmaLedger
presentation
ABV,
BAYER
MyData Online 2020
Conference
10-12
Decemb
er 2020
Virtual Provided by the European Connected Health
Alliance (ECHAlliance), which is the Global
Connector for Digital Health, facilitating multi-
stakeholder connections around ecosystems,
driving sustainable change in health and social care.
eConsent use
case
BI
Table 5: External Event in 2020

Presence
Participant
3rd Pharmacist
Conference - IMH Digital
Event
27
January
2021
Virtual The 3rd Pharmacists' Conference aims to analyze the
role of the modern pharmacies and how they have
been affected by the pandemic
"Transforming
Healthcare with
Blockchain."
NVS
International Blockchain
Forum Rotkreuz
4
February
2021
Virtual The fourth International Blockchain Forum focused on
the application of Blockchain technology in the
Healthcare sector.
PharmaLedger
Presentation NVS
Rx-360 Supply Chain
Security Steering
Committee
24
February
2021
Virtual The Supply Chain Security Steering Committee aims
to identify common gaps in the supply chain, with a
focus on supply chain security knowledge or practice
that can be best addressed through collaboration by
Consortium members to represent the biggest
opportunity to improve patient safety and product
integrity all while driving Rx-360’s mission to protect
patient safety.
PharmaLedger’s
member
presented an
introduction of
the project and
eight blockchain-
enabled use
cases.
NVS
Scope – Summit for
Clinical Ops Executives
2-4
March
2021
Virtual –
Orlando,
Florida
The 12th Annual Summit for Clinical Trials Operations
Executives (SCOPE) from the Cambridge Healthtech
Institute will cover various topics on Data Technology
for End-to-End Clinical Supply Management.
Project
introduction and
discussion in the
Fireside Chat
(Panel)
UPM, UCB,
EFGCP
PFE
Pharma Security Forum 8 March
2021
Virtual Pharma Security Forum 2021 is the cooperate virtual
gathering for the worldwide serialization, IT, track and
trace, supply chain, and manufacturing experts
Presented
"Leveraging
serialization for
patient value –
blockchain-
enabled
electronic
Product
Information
(ePI)."
NVS
Pharma Supply Chain &
Security World 2021
9-10
March
2021
Virtual The Annual Pharma Supply Chain and Security World
Summit is back in London for the 3rd time, and this
time with more focus on optimizing your supply chain
challenges.
PharmaLedger
presentation
GSK
4th Annual Pharma AI,
IoT & Blockchain 2021
11 March
2021
Virtual The 4th Annual Pharma AI, IoT & Blockchain 2021
covers Integrating AI, IoT, Blockchain & Big Data in
the Pharma and Healthcare industry.
Discussion at big
data and
blockchain
panels
UPM, NVS
GIRP Supply Chain
Conference
11 March
2021
Virtual The GIRP Supply Chain Conference brings together
healthcare and pharma supply chain experts from
Europe and across the globe to share insights in the
latest state-of-the-art supply chain and last mile
technologies, explore new options for value creation
in the healthcare ecosystem and provide a platform
for exchange amongst top level colleagues and peers.
Participated in
the discussion
"Driving the
Digital Supply
Chain"
NVS
DIA Europe 2021 15-19
March
2021
Virtual DIA Europe 2021 is Europe’s largest neutral
healthcare conference, which is attended by life
science professionals working in drug development,
from discovery to marketed use.
Virtual Booth
and 2 Spotlight
sessions
NVS, MSD,
KUL, BI
Blockchain Adria
Conference
25 March
2021
Virtual Blockchain Adria is the leading blockchain conference
in southeast Europe. Consisting of a series of online
events, this year's topics include smart contracts,
digital currency, record keeping and securities. The
first event this year will be Blockchain in Enterprise:
From Concept to Revenue. Keynote speech
NVS
Blockchain Conference
at University of Zurich
30 March
2021
Virtual PharmaLedger was presented in a blockchain lecture
series at the University of Zurich.
PharmaLedger
was presented in
a blockchain
lecture series
NVS
European Blockchain
Convention
12-16
April
2021
Virtual EBCvirtual is a comprehensive one-week event filled
with inspiring keynotes, panel discussions,
workshops, one-to-one meetings and high-level
networking.
"PharmaLedger
Track" panels
and Virtual
Booth
EFGCP,
KUL, BI,
UPM,
CERTH,
ONO, UCB,
OPBG,
MSD,
INCM, EPF,
NVS
LogiPharma 20 April
2021
Virtual The LogiPharma Europe event focuses on the
healthcare supply chain. This event focuses on the on
the Covid-19 distribution, how to leverage tech
Panel
NVS, MSD,
ABV, GSK

tranformation and redesigning suppy chain with
changes due to the pandemic.
Discussion
Innovation Talks at the
Danish Medicines
Agency
28 April
2021
Virtual On March 23 the Data Analytics Centre at the Danish
Medicines Agency launched a series of innovation
talks featuring the experts and initiatives that are
spearheading the development of advanced analytics
and data science related to medicines and medical
devices.
PharmaLedger
discussion
NOVO,
MSD, NVS
Global Clinical Trials
Connect 2021
5-6 May
2021
Virtual The 4th Annual Global Clinical Trials Connect 2021
focuses on collaboration, innovation, and enhancing
quality in clinical trials. This event will provide a
platform to discuss on the futuristic advancements in
clinical trials and clinical research. This
multidisciplinary program involves broad participation
of people from clinical trials community from around
the globe who are focused on learning more about
clinical research, clinical trials planning and
management.
PharmaLedger
Discussion:
Blockchain is not
only for Crypto.
Pharmaledger’s
journey through
its clinical trial
Use Cases:
eRecruitement
and eConsent.”
ONO
RX-360 Euro 2021
Virtual Conference
6 May
2021
Virtual Rx-360 is hosting a two day virtual conference that will
focus on supply chain integrity and patient safety
currently and post COVID-19.
Participate in a
panel discussion
around
PharmaLedger:
Blockchain-
Enabled
Healthcare,
followed by an
Rx-360
members-only
discussion
around
PharmaLedger.
NVS
Cambrex: Ensuring
Resilience As Priorities
Shift In Supply Chain
Management
18 May
2021
Virtual The COVID-19 pandemic placed significant pressure
on life sciences supply chains. Lockdowns, border
closures and remote working posed new challenges
for pharma companies and distribution of their
products. This led to pharma companies having to
reconsider their supply chain strategies and networks
to ensure their resilience. This virtual roundtable will
consider how life sciences companies reacted to
ensure supplies of critical medicines were maintained
in challenging circumstances, and how the crisis is
driving lasting change in the industry to manage future
risks.
Participate in the
discussion,
· Managing
elements of the
supply chain
internally vs.
outsourcing
· The potential
benefits of dual-
sourcing key
ingredients
· The future of
supply chains
NVS
Global Brand Protection
Innovation E-
Conference
16 June
2021
Virtual 11th Global Brand Protection Innovation Conference
2021 is an exclusive Online E-Conference designed
to discuss the latest challenges faced by the Brand
protection industry as a whole in this COVID-19
Pandemic situation. This one-day conference seeks
to expose explicit and hidden brand security
initiatives, as well as the global deployment of anti-
counterfeit technology, an analysis of diagnostic
approaches, recent technologies, serialization, track
& trace, and important brand security strategies.
PharmaLedger
Presentation
NVS
PHARMAP 2021
Congress
28-29
June,
2021
Virtual Pharmaceutical Manufacturing & Packing Congress
2021 is a B2B networking event for more than 250
Pharmaceuticals professionals from the whole value
chain of the industry. Pharmaceutical companies,
governmental bodies, CMOs, clinics, service
providers, startups, and other experts in
Pharmaceutical Manufacturing and Packaging are
gathering together to share experience, present their
case-studies and network.
Spoke on
"Leveraging
Serialisation for
Patient Value -
Blockchain-
enabled
electronic
Product
Information
(ePI).
NVS, MSD
Table 6: External Event in 2021

2.8 Liaison with other projects
The consortium has continued effective collaboration with other projects of the IMI programs. In
particular, the following collaborations have occurred and can be reported:
• Towards Gravitate Health (Involved partners: UPM, NVS)
• Towards Sapi (Involved partners: NVS, MSD)
• H2O (Involved partners: UPM)
2.9 Scientific Publication
During the second year of the project, one scientific paper was submitted and published. The detail of
the journal publication can be found below:
Type Title Authors Journal Status
Paper Blockchain
innovation in
pharmaceutical use
cases: PharmaLedger
and Mytigate
Yvonne Ziegler, Professor,
Vincenzo Uli, Research
Associate, Frankfurt University
of Applied Sciences and Jan
Wortmann, Bayer AG
Journal of Supply
Chain Management,
Logistics and
Procurement July
issue, Volume 3
Number 4, July 2021
Published
Table 7: Journal Publication
2.10 Demonstrations
In the second year, the consortium has levered on the interim release of the ePI platform based on
the electronic product information use case and carried out a virtual demonstration in DIA 2021
Europe. For this demonstration, an ePIbrochure has also been created.
Figure 5: PharmaLedger ePI Brochure

2.11 Coordination with other European Projects and Regulatory and
Standardisation Bodies
Along with PharmaLedger partner OBGP’s involvement with MyHealthMyData, PCDR (Paediatric
Cardiology Digital Repository), C4C (IMI2), INCiPiT (Italian Hub for the paediatric clinical trials),
GateKeeper (large scale project in healthcare UPM) and the industry partners’ involvement with
PhUSE Blockchain working group and EU Blockchain Observatory, the consortium members UPM and
NVS have developed effective collaboration with Gravitate Health.
PharmaLedger’s PMB and WP6.4 (Regulatory and Standardisation Engagement Strategy) participants
are actively engaging the ICH-GCP working group, HL7, EMA-ITF Task Force, US FDA, HMA-EMA Big
Data Steering committee, MHRA. More information on the engagement will be drafted in D6.9 and
D6.10.
3. NEXT PLANNED DISSEMINATION ACTIONS
3.1 Dissemination through external events
As part of continuous planning and improvement of the PharmaLedger dissemination actions, in year
2 and year 3, a significant number of events have been prepared and targeted.
Some of these events have offered the opportunity for the PharmaLedger consortium to keep
showcasing demos, sharing explainer videos for the use cases. At the same time, others will allow
disseminating at the European level project’s results and achievements, consolidating what has been
done during the first half and as a natural conclusion of the project itself.
During the second half of the project PharmaLedger will target conferences in healthcare, supply
chain, clinical trials, digital transformation.
The list of events planned for M19-M24 is presented in table 9. Looking at the major conferences we
attended during the first half of the project we have drawn a roadmap for the future major
conferences we can attend in Figure 7.
Presence
Participant
Insureblocks
Podcast:
PharmaLedger
- The
Pharmaceutica
l Blockchain
Consortium
7 July,
2021
Virtual Insureblocks is a dedicated
weekly podcast on
blockchain, smart
contracts and distributed
ledger technology (DLT).
Listen to the episide here
to hear a discussion
including: - The 5 A's of
Blockchain -
PharmaLedger use cases
- How our consortium
approach brings
competitors together - Our
next-generation
PharmaLedger
presentation
NVS

Presence
Participant
governance structure -
Blockchain-based
platform - COVID-19's
impact - Post-project
plans
King's
College
London Fight
the Fakes
Seminar
15 July,
2021
Virtual King's College London
Fight the Fakes Seminar
is a multidisciplinary
undergraduate and
postgraduate student-led
campaign with a primary
focus to raise awareness
on the global issue of
falsified, counterfeit and
substandard anti-infective
medicines particularly
antimalarials and
antibiotics which causes
several deaths annually
globally.
PharmaLedger
and the use of
blockchain in
the
pharmaceutical
industry,
followed by a 20
minute Q&A
session.
NVS
Blockchain
Pharma &
Life Sciences
Summit
23-24
August,
2021
Virtual
Blockchain Pharma & Life
Sciences Summit aims to
provide the most effective
ways to utilize blockchain
technology and the
potential implications for
the entire life sciences
ecosystem
Improving the
Quality and
Integrity of
Clinical Trial
Data and Use
Cases in
Blockchain:Phar
maLedger Anti-
Counterfeiting
UPM &
NVS
ISPE – EPFL
Workshop:
Pharma’s
Journey to
Digital
Manufacturin
g & Supply
30 Aug- 1
Sep, 2021
EPFL/ ETH
Campus
Lausanne
(Switzerland)
The ISPE – EPFL
Workshop: Pharma’s
Journey to Digital
Manufacturing & Supply is
a 3-day interactive
workshop for mid-senior
level managers and
professionals who seek to
master the efficiency and
speed of the digital
transformation towards
Pharma 4.0.
The essentials
of blockchain
technology and
PharmaLedger's
blockchain-
enabled use
cases.
NVS
Blockchain
Summit
Global
2-3
Septembe
r, 2021
Virtual Blockchain Summit Global
brings together the
world’s leading business,
finance, technology, legal,
government and opinion
leaders to advance the
mass adoption of
blockchain technology
panel discussion
"Use Cases of
Blockchain in
Healthcare"
NVS

Presence
Participant
Blockchain
Expo Global
2021
6 - 7
Septembe
r 2021
London The world-leading
Blockchain Expo series
returns to London and will
bring together key
industries from around the
world filled with top-
levelled discussions
across four co-located
events. The main topics
that will be discussed are
Blockchain, IoT, Cyber
Security & Cloud, AI and
Big data.
Fireside Chat:
Practical
Blockchain to
Solve Real
Problems Today
UCB
IPSF Innov8
Introductory
Workshop:
Application
of blockchain
technology in
community
pharmacy
services
INNOV8, an online
competition designed to
help International
Pharmaceutical Students'
Federation (IPSF)
members realise
innovative ideas.This
competition wants future
pharmacists to dig deeper
and help overcome health
issues in order to develop
better healthcare services
and public systems. This
online workshop will
introduce participants to
this competition and talk
about innovations
revolving around
pharmacy practice. More
information will be
released soon.
Workshop of
Blockchain
NVS, TVS
European
Identity and
Cloud
Conference
(EIC)
13-16
Septembe
r 2021
Munich,
Germany and
Virtual
The European Identity
and Cloud Conference is
the premier identity
conference featuring
industry leaders in
identity, cybersecurity,
and frontier technologies.
This four-day hybrid (on-
site and live) event
includes 250 sessions,
workshops and
networking opportunities.
Discussion
"Decentralisted
Identity in
Healthcare"
CERTH
EPF
Congress
2021
26-29
October
Virtual The EPF Congress 2021 is a
four day event bringing
the opportunity for
PharmaLedger
Booth and Use
case
presentation
TBC

Presence
Participant
dialogue and engagement
with a wide range of
health players who aspire
to showcase patient-led
innovation. Together, we
will explore what
meaningful patient
involvement means in a
rapidly changing
healthcare environment
using new technologies,
and why it is critical to
successful innovation.
DIA Japan
Annual
Meeting
24-26
October
Vitual DIA Japan Annual
Meeting bring together
stakeholders to look back
at what we have
accomplished and learned
during the COVID-19
pandemic and engage in
deeper dialogues as we
move to the next stage.
PharmaLedger
presentation
TBC
BioData
World
Congress
2-4 Nov
2021
Basel,
Switzerland
BioData World Congress
is Europe’s largest
congress covering big
data in pharmaceutical
development and
healthcare. Genomics
Live runs in tandem with
BioData World Congress
and covers all facets of
precision medicine,
multiomics and
diagnostics.
discussion
"PharmaLedger
EU Block Chain
Project,"
NVS

Figure 6: Roadmap for the Future Conferences
3.2 Open Access Scientific Publication
The initial planning of the open-source scientific publication, examples of domain/discipline related
to PharmaLedger outcomes (Table 8) etc., have been shared with the steering committee in June 2021.
According to the planning, WP1 (Business Use Case), WP2 (Implementation and Solutions), WP3
(Architecture and Reference Implementation), WP4 (Governance), and WP5 (Regulatory, Legal and
Data Privacy) actors/contributors will be responsible for publishing the PharmaLedger outcomes, and
WP6 (Culture and Adoption) will facilitate the process. Initially, the focus areas are the following but
are not limited to
• Cryptography
• Blockchain Technology & Application
o PharmaLedger Architecture
o Open DSU
• Pilots/Trials Results
• Governance
• Legal and Privacy Aspects
The following table gives an example of the potential domain/discipline for the scientific publication:

Domain /
Discipline
Publisher Type Title
Impact
Factor
OpenAcc
ess(Y/N)
Link Fee (Link)
Blockchain
Technology
Springer Journal Cluster Computing
The Journal of
Networks, Software
Tools and
Applications
3.458 Y https://www.spring
er.com/journal/105
86
https://www.springer.co
m/journal/10586/open-
access-
publishing#Fees%20and%
20Funding
Blockchain
Technology &
Application
Elsevier Journal Blockchain:
Research and
Applications
N/A Y https://www.journal
s.elsevier.com/block
chain-research-and-
applications
https://www.elsevier.co
m/journals/blockchain:re
search-and-
applications/2096-
7209/open-access-journal
Blockchain
Technology &
Application
IEEE Journal IEEE Transactions on
Emerging Topics
inComputing
6.043 Y https://ieeexplore.ie
ee.org/xpl/RecentIss
ue.jsp?punumber=6
245516
https://journals.ieeeauth
orcenter.ieee.org/choose
-a-publishing-
agreement/open-access-
rights-management/
Blockchain in
Industry,Blockc
hainTechnologi
es
Frontiers
Media SA
Journal Frontiers in
Blockchain
N/A Y https://www.frontie
rsin.org/journals/blo
ckchain - about
https://www.frontiersin.o
rg/about/publishing-fees
Blockchain
Application
PLOS Journal PLoS One https://journals.plos
.org/plosone/search
?q=blockchain&filter
Journals=PLoSONE
Available upon
request authorbilling@pl
os.org
Blockchain
Application
MDPI Journal Journal of Open
Innovation:
Technology,Market,
and Complexity
N/A Y https://www.mdpi.c
om/journal/joitmc
https://www.mdpi.com/j
ournal/JOItmC/apc
Blockchain
(Privacy &Legal
Aspects)
IEEE Magazin
e
IEEE Security &
Privacy
2.04 Y https://ieeexplore.ie
ee.org/xpl/RecentIss
ue.jsp?punumber=8
013
https://journals.ieeeauth
orcenter.ieee.org/choose
-a-publishing-
agreement/open-access-
rights-management/
Cryptography MDPI Journal Cryptography N/A Y https://www.mdpi.c
om/journal/cryptogr
aphy
https://www.mdpi.com/j
ournal/cryptography/apc
Cryptography Springer Journal Journal of
Cryptology
1.277 Y https://www.spring
er.com/journal/145/
https://www.springer.co
m/journal/145/open-
access-
publishing#Fees%20and%
20Funding
Table 8: Examples of Potential Scientific Journals

4. EXPLOITATION ACTIVITIES
As mentioned in the initial dissemination and exploitation strategy document (D6.11), PharmaLedger
has focused on a change management perspective at an early stage of the project. PharmaLedger
partners have considered “raising the awareness of blockchain as a paradigm shift in the healthcare
ecosystem” in all communication, dissemination and exploitation activities.
PharmaLedger is digitally transforming the healthcare ecosystem into a blockchain-enabled
healthcare ecosystem supported by OpenDSU, open-source, decentralised access control and self-
sovereign applications.
In the first half of the project lifetime, the consortium has selected 8 use cases in three domains:
supply chain, clinical trial, and health data.
Figure 7: PharmaLedger use cases
PharmaLedger’s results are based on the OpenDSU and 8 use cases that will continue to grow and
appear after the end of the project. According to the Dissemination and Exploitation (D&E) obligations
and opportunities beyond the end of the grant H2020 and articles 28 and 29 of the grant agreement,
all beneficiaries of PharmaLedger will continue to exploit and disseminate the project results up to
four years beyond the project. The ways of exploiting the result can be done by the following but are
not limited to:
• Utilising the result in further research activities (outside the action)
• Developing, creating, marketing and providing a product, process or service
• Applying the results and processes in standardisation activities
As part of updated Exploitation planning and activities, WP6 has taken several steps that would be
continuously updated. The final exploitable results will be developed in the final report of exploitation
and sustainability (D6.14).
WP6 has updated the exploitation plan with the following steps

• Exploitable Results
• Exploitation Routes
• Individual Exploitation Plan
• Business Plan and Sustainability
Figure 8: Exploitation Planning, Activities and Timeline
4.1 Identification of the Exploitation Results and Stakeholders
As a first step of the exploitation activities, WP6 has identified the most prominent exploitable results
for the PharmaLedger project. This list will be reviewed and improved in a continuous manner.
Exploitable Results Lead Partners
PharmaLedger Blockchain enabled Ecosystem
based on the Open DSU
Pharma Stakeholders, Technical Stakeholders
Use Case: Electronic Product Information, ePi
or eLeaflet
Pharma Use case Leads, MVP Leads, co-Leads
and participants
Use Case: Clinical Supply Pharma Use case Leads, MVP Leads, co-Leads
and participants
Use Case: Finished Goods Traceability Pharma Use case Leads, MVP Leads, co-Leads
and participants
Use Case: Anticounterfeiting Pharma Use case Leads, MVP Leads, co-Leads
and participants
Use Case: eConsent Pharma Use case Leads, MVP Leads, co-Leads
and participants
Use Case: Clinical Trials Recruitment or
eRecruitment
Pharma Use case Leads, MVP Leads, co-Leads
and participants
M1 M6 M12 M18 M24 M30 M36
D6.12 D6.14
D6.12 D6.14
D6.12 D6.14
D6.14
Identification of the Exploitable Results &
Stakeholders
Governance Options for the Exploitation Routes
Individual Exploitation Plan
Business Plan & Sustainability

Exploitable Results Lead Partners
Use Case: IoT and Personalized Medicine Pharma Use case Leads, MVP Leads, co-Leads
and participants
Collaboration Platform EKON
4.2 Governance Options for the Exploitation Routes
Once the exploitable results are identified, governance options for the exploration routes can be
tailored to each. These routes revolve around
• The use of further research
• Developing and selling new products and/or services
• Spin-off activities
• Cooperation agreement/ Joint Ventures
• Selling IP rights or IP related business
• Licensing
Phamaledger’s overall exploitation planning and activities largely depend on the governance, and the
operating model is chosen for the post-project implementation. PharmaLedger WP4 Governance and
Operating Model have mapped four governance models (Ecosystem Led, Service Provider Led,
Foundation Led (independent) and Foundation Led (Ecosystem Governed) and recommended both
Ecosystem Led and Foundation Led (Ecosystem Governed) governance model. A detailed overview of
the governance options and recommended models can be found in D4.1 and D4.2.
Figure 9: Recommended Post-PharmaLedger Operating Model7
7
D4.2 Governance Recommendation

WP6 will continue to align the exploitation plan with the final recommended governances proposed
by WP4, and these detailed exploitation activities will be drafted as a report in D6.14 Final Exploitation
Activities and Sustainability.
4.3 Individual Exploitation Plan
After the list of exploitable results is finalised, the lead stakeholders will be contacted for the individual
exploitation plan. PharmaLedger consortium can be clustered in 5 types of beneficiaries, described
briefly below:
4.3.1 Pharma Stakeholders:
The pharma stakeholders will be the key beneficiaries and the first adopters of the exploitable results.
They will utilise a change management methodology for the adoption of blockchain-enabled
healthcare solutions to the ecosystem. They will also be key stakeholders for the governance.
4.3.2 Technical Stakeholders:
The technical service providers, for example, the SMEs will be actively involved in the governance,
further development of the blockchain- related solutions, further research opportunities and exploit
the results through creating training materials.
4.3.3 Hospitals:
The hospitals will be the adopters of the relevant blockchain solutions.
4.3.4 Patient Organisations:
The patient organisations will be the adopters of the relevant blockchain solutions and will be actively
involved in the governance.
4.3.5 Universities and Research Organisations:
The universities and research organisations will be actively involved in the governance, further
development of the blockchain-related solutions, further research opportunities and exploit the
results through creating academic and training materials.
A comprehensive plan for individual exploitation plans and activities will be provided in D6.14.
4.4 Business Plan
PharmaLedger’s goal for the exploitation activities will be to provide a comprehensive view of the
market possibilities, PharmaLedger offerings and business models for a blockchain-based solution for
the healthcare ecosystem. In order to assess the viability for the PharmaLedger project as well as the
sustainability to implement a Go to Market Strategy after the project conclusion, WP6 structures this
step in different phases to evaluate the potential of PharmaLedger. The following details only
summarise the further steps that will be elaborated in D6.14.

4.4.1 Phase 1 Market Analysis:
The Phase 1 market analysis will start by exploring the current state of the art of blockchain-focused
healthcare ecosystem. Afterwards, similar initiatives and projects within the same framework as
PharmaLedger will be evaluated in order to have a better approach of what already exists or is
currently being developed and what PharmaLedger can offer as a differentiator factor.
The global blockchain market size was estimated at 3.06 billion in 2020, with significant growth of
52.4% in 2020 compared to the average year-on-year growth during 2017-20198
. While the blockchain
market in healthcare itself was valued at 2.12 billion in 2020, with an average growth of 8.7% during
the forecast period, 2021-20269
. North America has been identified as the fastest growing and largest
blockchain in the healthcare market.
8
Blockchain Market Size, Share & Statistics | Forecast [2028].
https://www.fortunebusinessinsights.com/industry-reports/blockchain-market-100072.
9
Blockchain Market in Healthcare | 2021 - 26 | Industry Share, Size, Growth - Mordor Intelligence.
https://www.mordorintelligence.com/industry-reports/blockchain-market-in-healthcare.

Figure 10: Different Phases of the Business Plan
4.4.2 Phase 2 Competitor’s Analysis:
A study and assessment of the current and potential companies that PharmaLedger expects to
compete with due to covering the same scope. The objective of the Competitors’ analysis is to develop
a profile of each competitor to help define strategic positioning/competitive advantages and lay the
foundation for determining the PharmaLedger value-added and positioning in the market.
Some of the key market players are identified by PharmaLedger. They are Hashed Health (USA),
Guardtime (Estonia), PokitDok (USA), IBM (USA), Microsoft (USA), Proof. Work (UK), SimplyVital
Health (USA), FarmaTrust (UK), Blockpharma (France), Medical Chain (UK), MediLedger (USA), Factom
(USA) etc.
Phase 3:
Stakeholder
Analysis
Phase 2 :
Competit
ors'
Analysis
Phase 1:
Market
Analysis
Phase 5:
Business Model
Value
Proposition
Phase 6:
IPR and
Licenses
Phase 4:
SWOT
Phase 7:
Financial
Planning and
Revenue
Model
Phase 8:
Marketin
g Plan

A detailed analysis of the competitors based on activities, key blockchain-based services, geographical
location, partnerships, pricing, business model, strengths, weaknesses, etc. will be drafted in D6.14.
4.4.3 Phase 3 SWOT
Once the current market is explored, and the competitive analysis analysed, the next step is to conduct
a SWOT Analysis. Conducting a SWOT analysis will help to understand the internal and external factors
to define the value proposition of PharmaLedger. Overall, the SWOT provides a list of barriers
(weaknesses and threats) and drivers (strengths and opportunities). A technical and organisational
point of view for the SWOT analysis will be considered and taken into account in the following versions
of this deliverable:
• Strength
o Support for further development of the novel Open DSU and platforms.
o Defined use cases in supply chain, clinical trial, and health data area.
o Scalability and Interoperability.
o Open source technology.
o Patient focused solutions
o Participation of multiple partners with different expertise facilities the building of a
robust platform and open opportunities for future collaborations especially on the
sustainability of the platform.
• Weakness
o Support, maintenance and operational costs.
o The documentation for the OpenDSU is in a preliminary stage
o Securities of the involved systems which are developing are not guaranteed.
o Sustainable concrete and clear business model.
o No standard roadmap for technology adoptions.
• Opportunity
o During Covid-19 the demand for blockchain in healthcare has increased
o Rapid growth of blockchain technologies in healthcare
o Low competition offering the same type of concept.
o Increase need for data ownership, patient consent, IoT devices.
o Technical expertise from partners in different blockchain applications.
• Threats
o No governance model has been established for commercialisation.
o Limited or no funding beyond the length of the project.
o Platform sustainability once the project has finalised.
o Functionalities issues by integrating all use cases.
o Highly Innovative concept.
4.4.4 Phase 4 Stakeholder Analysis
The next step is to conduct a stakeholder mapping process in order to identify which stakeholders
need to be engaged to achieve the highest impact for the project. It is crucial to ensure that the

PharmaLedger project engages with the right stakeholders from its early stages and that no effort is
being wasted to communicate to the audiences that are less relevant to the project. For these reasons,
during the second year of the PharmaLedger, the main aim has been to conduct a stakeholder
mapping process in order to identify which stakeholders need to be engaged to achieve the highest
impact for the project.
Figure 11: Stakeholder Engagement process
For the Stakeholders’ Mapping, the Consortium has used the Power Interest Grid, which is also known
as the Power Interest Matrix, a simple tool that helps to categorise project stakeholders with
increasing power and interest in the project. For that, a first step has been to identify the list of
stakeholders that may be interested in such a project.
Identify and
Segmentation of the
Stakeholders
Analyse Stakeholders
by Impact and
Influence
Plan Stakeholder
Communication
Enage with
Stakeholders

A second step has been to classify all the stakeholders into four categories based on their interests,
benefits obtained and power of influence10
:
• High power - High interest (Manage Closely): these stakeholders are decision-makers and
have the biggest impact on the project success, and hence their expectations must be closely
managed.
• High power - Low Interest (Keep Satisfied): these stakeholders need to be kept in the loop
and satisfied, even though they are not interested because they yield power. This type of
stakeholders should be dealt with cautiously as well, since they may use their power in a not
desired way in the project if they become unsatisfied.
• Low power – High interest (Keep informed): people to keep adequately informed and talk
to them to ensure that no major issues are arising. They can often be very helpful with the
details of the project.
• Low power - Low interest (Monitor): These people should be monitored but not be bothered
by excessive communication.
Figure 12: Sample Stakeholder mapping
The third step on the procedure, once stakeholders have been classified into these four categories, is
to define the communication plan for finally engaging them. The key stakeholders will be analysed in
terms of challenges, what aspects of PharmaLedger are they likely to be interested in, Times or context
in which they have more/less influence over the outcomes of PharmaLedger, ways they might block
or facilitate the PharmaLedger impact, key message etc.
10
ProjectManagement.com - Stakeholder Analysis using the Power Interest Grid

4.4.5 Phase 5 Business Model Value Proposition
A business model canvas and value proposition for the whole solution provided by PharmaLedger will
support the strategy of the business plan to identify for whom the consortium is solving the problem;
how we create customer value; how PharmaLedger will be distributed to stakeholders; how
PharmaLedger will stay competitive; and all revenue and costs that can be anticipated.
4.4.6 Phase 6 IPR and Licenses
An effective business plan will depend on the proper management of the intellectual property. It
would be valuable to assess whether there are some activities related to IPR, namely, assessment of
pre-existing of the project partners, assessment of the results generated during the project, a
proposition of the optimal IPR protection options, ownership and proper implementation of IPR
protection measures.
4.4.7 Phase 7 Financial Planning & Revenue Models
The Financial Plan component of the Business Plan is a statement of PharmaLedger current financial
position, its projected financial situation over time as the business grows, its strategy for seeking
investors, and its Exit Strategy. It is crucial for determining the business model's viability and essential
for lenders and investors who want to see hard figures before putting money into your company.
4.4.8 Phase 8 Marketing Plan
The Marketing Plan is the tactical plan for taking all of the business plan's internal analysis and strategy
components and turning them into a "plan of action" used to engage the external market of potential
users and partners.
Considering the stage of PharmaLedger development, it is more beneficial to reason on the Marketing
Funnel Phases and how they can be aligned with PharmaLedger's communication and dissemination
activities. In essence, how we can transform project results, outcomes during project implementation,
and outcomes of actions after the project ends.
Figure 13: Content Marketing Funnel
The typical phases of the marketing funnel are Awareness, Evaluation, Conversion and Delight. During
the awareness phase, we must assume that potential stakeholders are not aware of neither the
consortium nor the solutions we are providing. It is our job to educate potential users on the
Awareness
Evaluation
Conversion
Delight

challenges they are facing and on potential solutions. In the Evaluation phase, potential users know
that they have a problem and are aware of our solution. It is our job to build trust so that they decide
that the PharmaLedger platform is the solution for their challenges. In the conversion phase, potential
users are convinced that our solution is the answer to their challenges, and it is our job to provide
clear reasons for them to decide that investing in PharmaLedger is the smart thing to do. Finally, in
the delight phase, users that have bought our solution are invited to provide feedback and generate
new content. It is our job to make sure that they are communicating with us, providing feedback on
PharmaLedger and referrals to other potential users.
Awareness Phase
The awareness phase has already started; it is part of the communication and dissemination strategy
of PharmaLedger. We are interacting with different stakeholders (such as through the patient
organisations) to collect their needs and present the goals, and the PharmaLedger use cases and
platforms. We are specifically using the following content types:
• Shareable blog posts with text and infographics on PharmaLedger website and newsletters
• Social media posts on Twitter, LinkedIn, and YouTube
• Videos for which we have a roadmap
• PharmaLedger official presentation to be shared for events, workshops and meetings
The evaluation of the effectiveness of the tools implemented is being assessed with communication
and dissemination KPIs of the project. However, there are two aspects that need to be revisited. The
first is the fact that that the targets of PharmaLedger communication and dissemination strategy are
fully aligned with the stakeholders mapping. The second aspect is that the Communication and
Dissemination plan of PharmaLedger is time-bounded to the project duration.
Evaluation Phase
As mentioned, the key goal of the evaluation is to build trust in the potential users (T2.6). Essentially
potential users need to be confident that:
• They have a problem that needs to be addressed,
• Among the multiple options available, the PharmaLedger framework is the solution.
PharmaLedger use case pilots are the kick-off for this phase and the major contributor to
building trust across the ecosystem. They already involve representatives of stakeholders
identified in the Stakeholder mapping and demonstrate how PharmaLedger is used in 8 use
cases scenarios.
In the timeline of PharmaLedger project implementation and validation, we will be able to produce:
• Case studies documenting the pilots, namely the problems or challenges and how they were
addressed
• White papers to documenting challenges and they be solved using PharmaLedger framework
• Useful resources or downloads, for example, scientific papers describing how PharmaLedger
addresses specific needs
• Events and webinars, where the PharmaLedger project members address multiple
perspectives of the project.

In terms of monitoring the success of the methodology, we will monitor closely indicators that may
reveal:
• Are people converting with this content?
• Is the available content-generating new leads or interests?
• Is the content helping or hurting their goals?
Conversion Phase
During this phase, we will need to close the deals with the potential users. By this phase, users will
have identified problems or challenges to be addressed, know about the PharmaLedger and the
services, and we will be ready to close the sale. In order to close the sale, we need to make sure that:
• The digital content has a clear call to action.
• The purchase process is as simple as possible. This will be possible by evaluating different
revenue models. The strategy to close the sales will be fine-tuned according to the concrete
licensing chosen.
Delight Phase
From the marketing perspective, In the Delight phase, we will need to engage with existing users to
make sure that they help PharmaLedger improve the product and bring new users to the marketing
funnel. We need to keep building an audience and make sure that they are engaged. The digital
presence of PharmaLedger needs to make sure that:
• Clients are encouraged to leave feedback
• Publications provide reasons for readers to share and refer to other peers
• Contents showcase real user success

5. CONCLUSION
This deliverable describes the results of dissemination and exploitation activities carried out during
the first half (M1-M18) of the PharmaLedger project. In summary, we can affirm that the consortium
has successfully built a consistent and relevant impact through its dissemination activities. However,
regarding the dissemination actions, we must highlight and improve the relevant presence at the
academic conferences during the second half of the project, maximising the visibility of project
concepts, progress, and results.
The consortium has already achieved a high level of relevance participating in the pharma supply
chain, clinical trials and blockchain-related international conferences. Regarding publishing the project
results in relevant conferences, we must highlight the outcome of published papers. These papers will
result from collaborations between PharmaLedger work package leaders, use cases leaders, co-
leaders and contributors from the PharmaLedger partners.
The document also presents the planned exploitation activities that will reflect on the PharmaLedger
post-project governance and operating model. Overall, the first half of the project has been very
productive for the communications, dissemination, and exploitation activities in the project, which
shall continue in the next period until the end of the project.
This version needs a future revision and extension of the planning, at a later stage of the project, in
M36. During the third year of the project, we will have the final financial plan that will be the basis to
ensure the sustainability and operation of the PharmaLedger outcomes after the project’s conclusion
and the revenue models. In addition, we will consider feedback gathered from the user's perspective
during pilot trials to redefine the exploitation plan of PharmaLedger and the sustainability of the
PharmaLedger framework. Finally, the last deliverable (D6.14) will include an update of the Business
Model Canvas from the different use cases that validate PharmaLedger.

APPENDIX
Annex 1: News Mentions and Featured Articles
News Mentions & Featured Articles Original Date Posted
Ledger Insights: 12 global pharmaceutical firms join EU blockchain
consortium PharmaLedger
3 Mar 2020
Blockchain Magazine: EU-backed Blockchain Consortium PharmaLedger
Declares Use Cases
1 July 2020
The Block: EU health blockchain consortium PharmaLedger reveals first
use cases
1 July 2020
Romsoft: PharmaLedger: The Blockchain revolution is happening 27 January 2021
Forbes: Pharma’s Blockchain Trials: Novartis, Merck Test The Tech
Popularized By Bitcoin 2 February 2021
Romsoft: The Future of Clinical Trials with PharmaLedger 12 February 2021
Hashed Health Newsletter: Enterprise Healthcare Blockchain Consortia:
PharmaLedger's Governance First Approach 1 February 2021
Romsoft: PharmaLedger to address drug counterfeiting March 2021
Blockchain in Sanità: the PharmaLedger projectt 21 April 2021
Romsoft: The Personalized Medicine use case in PharmaLedger June 2021
Crypto News: Chinese University to Offer Undergrad Blockchain Degree +
More News 4 March, 2020
Blockchain: Opportunities for healthcare: CONNECT University Pēteris
Zilgalvis (Head of Unit, DG CONNECT), 29 Sep 2020
IPI: End-to-end Visibility -The Foundation of Addressing Today’s Challenges
in Pharmaceutical Distribution 6 November 2020
Jurnal Virtual: The Iasi company RomSoft provides Blockchain technology
for safer medicines 3 December 2020

Glocurex: Are blockchain and cryptocurrencies promise of a brighter
future? 25 November 2020
Deloitte: The after-effects of the pandemic on life sciences ecosystems End of 2020
TICPharma: Blockchain in pharma: promises fly, use cases remain 5 December 2020
Coindesk: Enterprise Blockchain Is at a Private-Public Crossroads 6 January 2021
Forbes: Blockchain 50 2021 2 February 2021
VWV: How Might Blockchain Impact the Pharmaceutical Supply Chain? 18 January 2021
Fortune India: Covid-19 vaccine: How ready is India’s supply chain? 1 March 2021
Hashed Health: Enterprise Healthcare Blockchain Consortia:
PharmaLedger's Governance First Approach March 2021
Insureblocks Podcast: Ep. 152 – Blockchain insurance innovation – insights
from Tata Consultancy Services 14 March 2021
OriginTrail Decentralized Knowledge Graph (DKG) as the technology
backbone of the life sciences and healthcare industry: Trace Labs General
Manager’s point of view 7 April 2021
IMI Impact: Driving healthcare’s digital future 16 March 2021
Corriere della Sera: Blockchain, now everyone wants it: fashion, vaccines
and football, how it works 11 May 2021
Internet of Things and shared records: the technology that drives vaccines
and drug May 12, 2021
Two Featured Articles by Forbes
https://www.forbes.com/sites/katiejennings/2021/02/02/pharmas-blockchain-trials-novartis-
merck-test-the-tech-popularized-by-bitcoin/?sh=66047cdd7e86

https://www.forbes.com/sites/michaeldelcastillo/2021/02/02/blockchain-50/?sh=4d854740231c

Annex 2: Blog Posts
Blog post
Date
Posted Link
2020
1
PharmaLedger:
Blockchain Enabled
Healtchare
14-Aug-
2020
https://pharmaledger.eu/news/pharmaledger-blockchain-
enabled-healthcare/
2
#1 PharmaLedger Internal
Webinar - "From Design
to Development"
1-Sep-
2020
https://pharmaledger.eu/news/1-pharmaledger-webinar-
from-design-to-development/
3
New Collaboration -
European Blockchain
Convention
15-Oct-
2020
https://pharmaledger.eu/news/new-collaboration-european-
blockchain-convention/
4
PharmaLedger Presence:
European Blockchain
Convention 2020 Virtual
Edition
9-Nov-
2020
https://pharmaledger.eu/news/pharmaledgers-presence-
european-blockchain-convention-2020-virtual-edition/
5
Challenges Found in
Healthcare Supply Chains
25-Nov-
2020
https://pharmaledger.eu/news/pharmaledger-challenges-
found-in-healthcare-supply-chains/
6
Rewatch PharmaLedger's
First Open Webinar: "A
Trust-Centric Healthcare
Joruney
17-Dec-
2020
https://pharmaledger.eu/news/rewatch-pharmaledgers-first-
open-webinar-a-trust-centric-healthcare-journey/
7
PharmaLedger 2020 End
of Year Press Release
18-Dec-
2020 https://pharmaledger.eu/news/end-year-press-release/
2021
1
Celebrating the One-Year
Anniversary of the
PharmaLedger Project
14-Jan-
2021
https://pharmaledger.eu/news/celebrating-the-one-year-
anniversary-of-the-pharmaledger-project/
2
1. PharmaLedger's
Clinical Supply
Traceability Use Case
15-Jan-
2021
https://pharmaledger.eu/news/1-pharmaledgers-clinical-
supply-traceability-use-case/

Blog post
Date
Posted Link
3
2. PharmaLedger's
Finished Goods
Traceability Use Case
20-Jan-
2021
https://pharmaledger.eu/news/2-pharmaledgers-finished-
goods-traceability-use-case/
4
3. PharmaLedger's ePI -
Electronic Product
Information Use Case
3-Feb-
2021
https://pharmaledger.eu/news/3-pharmaledgers-epi-
electronic-product-information-use-case/
5
4. PharmaLedger's Anti-
Counterfeiting Use Case
5-Feb-
2021
https://pharmaledger.eu/news/4-pharmaledgers-anti-
counterfeiting-use-case/
6
EFGCP: Bringing the
Patient Voice to the
PharmaLedger Project
23-Feb-
2021
https://pharmaledger.eu/news/efgcp-bringing-the-patient-
voice-to-the-pharmaledger-project/
7
New Collaboration:
PharmaLedger x
LogiPharma Transforming
Healthcare Supply Chains
13-Mar-
2021
https://pharmaledger.eu/news/new-collaboration-
pharmaledger-x-logipharma-transforming-healthcare-
supply-chains/
8
A Trust-Centric
Healthcare Journey Part
II: Challenges Found in
Clinical Trials and Health
Data
17-Mar-
2021
https://pharmaledger.eu/news/a-trust-centric-healthcare-
journey-part-ii-challenges-found-in-clinical-trials-and-health-
data/
9
1. PharmaLedger's
Clinical Trial eRecruitment
Use Case
22-
April-
2021
https://pharmaledger.eu/news/1-pharmaledgers-clinical-trial-
erecruitment-use-case/
10
2. PharmaLedger's
Clinical Trial eConsent
Use Case
27-
April-
2021
https://pharmaledger.eu/news/2-pharmaledgers-clinical-trial-
econsent-use-case/
11
Advancing Health
Priorities at DIA Europe
2021
2-May-
2021
https://pharmaledger.eu/news/advancing-health-priorities-
pharmaledger-at-dia-europe-2021/
12
3. PharmaLedger's IoT
Medical Devices Use
Case
4-May-
2021
https://pharmaledger.eu/news/3-pharmaledgers-iot-medical-
device-use-case/
13
4. PharmaLedger's
Personalised Medicine
Use Case
11-May-
2021
https://pharmaledger.eu/news/4-pharmaledgers-
personalised-medicine-use-case/

Blog post
Date
Posted Link
14
PharmaLedger Presence:
European Blockchain
Convention Virtual Edition
2021
13-May-
2021
https://pharmaledger.eu/news/pharmaledger-track-
introduction-at-the-european-blockchain-convention-2021/
15 EBC #1
25-May-
2021
https://pharmaledger.eu/news/pharmaledger-track-panel-1-
healthcare-data-privacy-ownership-european-blockchain-
convention-2021/
16 EBC #2
1-June-
2021
powering-clinical-trials-with-iot-and-blockchain-european-
blockchain-convention-2021/
17 EBC #3
8-June-
2021
can-blockchain-prevent-the-problem-of-counterfeit-drugs-
european-blockchain-convention-2021/
18 EBC #4
14-
June-
2021
verifiable-credentials-for-covid-19-data-management-
european-blockchain-convention-2021/

Annex 3: PharmaLedger Videos
1. PharmaLedger: Introduction-KickOff
2. Blockchain Explained - What is Blockchain?
3. PharmaLedger Explainer Video: Electronic Product Information (ePI) Use Case
4. Topic 1 - Clinical Supply Traceability | #1 Webinar | A Trust-Centric Healthcare Journey
5. Topic 2 - Finished Goods Traceability | #1 Webinar | A Trust-Centric Healthcare Journey
6. Topic 3 - ePI - Electronic Product | #1 Webinar | A Trust-Centric Healthcare Journey
7. Topic 4 - Anti Counterfeiting | #1 Webinar | A Trust-Centric Healthcare Journey
8. Full Recording | PharmaLedger #1 Webinar | A Trust-Centric Healthcare Journey
9. Introduction | #2 Webinar | A Trust-Centric Healthcare Journey Part II
10. Topic 1 - Clinical Trial eRecruitment + Q&A | #2 Webinar | A Trust-Centric Healthcare Journey
II
11. Topic 2 - Clinical Trial eConsent + Q&A | #2 Webinar | A Trust-Centric Healthcare Journey II
12. Topic 3 - IoT Medical Devices + Q&A | #2 Webinar | A Trust-Centric Healthcare Journey II
13. Topic 4 - Personalised Medicine + Q&A | #2 Webinar | A Trust-Centric Healthcare Journey II
14. Full Recording | PharmaLedger #2 Webinar | A Trust-Centric Healthcare Journey Part II
15. PharmaLedger at SCOPE Virtual Summit | March 2, 2021
16. Spotlight Session #1: Demonstrating the Vision of Blockchain-Enabled Healthcare | DIA
Europe 2021
17. Spotlight Session #2: Data Privacy and the Vision of Blockchain-Enabled Healthcare | DIA
Europe 2021

PharmaLedger – First Report on Dissemination and Exploitation Activities

Recommended

Recommended

More Related Content

What's hot

What's hot (7)

Similar to PharmaLedger – First Report on Dissemination and Exploitation Activities

Similar to PharmaLedger – First Report on Dissemination and Exploitation Activities (20)

More from PharmaLedger

More from PharmaLedger (12)

Recently uploaded

Recently uploaded (20)

PharmaLedger – First Report on Dissemination and Exploitation Activities